Dreamtech has developed a diagnostic device that can detect whether a patient has contracted COVID-19 in 30 seconds, the company said Friday.
The device was co-developed with Israeli start-up Nanoscent, and uses the company’s electronic nose solution.
It detects volatile organic compound from patient’s breath to see whether they have contracted the virus.
Dreamtech said its device was more convenient than temperature measurement or test kits currently used to check for COVID-19.
The device can also detect the virus from asymptomatic patients, the company said.
Applying the device for check-ups at airports or crowded areas will save cost considerably, it added.
Dreamtech and Nanoscent plan to modulate the device and pair it with designated breathing bags.
They will supply 500 of the devices and 100,000 bags by August to clients.
The two will seek approval from Europe’s CE in the third quarter, followed by the US’s FDA and Israel’s AMAR to export the goods.
Dreamtech invested a million dollars in Nanoscent in March last year, to become the exclusive vendor for the electronic nose solution.
The technology is also being funded by the Korea-Israel Industrial R&D Foundation. The two companies plan to invest US$4 million in the next 27 months into research and development to upgrade the technology further.